Webinar - The Government’s Role in Driving Pharmaceutical Innovation

One of government’s core duties is to ensure a robust healthcare system that guarantees access to high-quality care and novel medicines that meet the health needs of the population. Achieving this goal necessitates a well-functioning pharmaceutical innovation system as a foundational prerequisite

For the pharmaceutical innovation system to thrive and continually push beyond the state of the art, governments, in the first place, play a pivotal role in creating an environment conducive to innovation by implementing policies and incentives that encourage and reward initiative and investment by industry in the research and development of novel medicines. – Government as enabler and incentivizer of pharmaceutical innovation

Sustainable access to novel medicines has, however, emerged as a growing concern for governments. The output of the pharmaceutical innovation system and patient needs are often perceived as misaligned, or concerns linger about the availability and affordability of such output. Governments are actively addressing these barriers by intervening (including through regulations, more stringent funding conditions, and stricter market access terms) to ensure the accessibility, availability and affordability of novel medicines. – Government as regulator of pharmaceutical innovation

To further confront the challenge of ensuring sustainable access to novel medicines, governments have embraced an even more proactive approach in recent years, by spearheading initiatives aimed at directly influencing the innovation pipeline. By taking ownership of strategic innovation planning, governments seek to anticipate future healthcare needs, and drive targeted research and development efforts, thereby exerting a direct impact on the innovation output – Government as contributor to pharmaceutical innovation